Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis

Siegfried, Elaine C.; Korman, Neil J.; Molina, Carmen; Kianifard, Farid; Abrams, Ken

doi:10.1080/09546630600647297

Cited by 44 publications

(56 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This efficacy benefit was also reflected in an increased compliance and hence lower discontinuation rates (11.8% in the pimecrolimus arm and 42.4% in the vehicle arm). Overall, these findings confirm the clinical efficacy of pimecrolimus cream 1% in preventing acute exacerbations of AD during early disease or relapse during the remission time [24,25,26,27,28,29]. …”

Section: Discussionsupporting

confidence: 73%

See 1 more Smart Citation

Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial

Bangert

Strober²,

Cork³

et al. 2010

Dermatology

View full text Add to dashboard Cite

Background: Topical pimecrolimus may maintain remissions of atopic dermatitis (AD) by inhibiting subclinical inflammation. Objective: To evaluate clinical and cytological effects of pimecrolimus in topical corticosteroid-treated and resolved AD lesions. Methods: Patients (n = 67) with resolved AD lesions were randomized to 3-week double-blind treatment with either pimecrolimus cream 1% or vehicle cream. Outcome measures were reduction in Eczema Area and Severity Index (EASI) and number of leukocytes in skin biopsies in all randomized patients who were evaluable at the end of study. Results: The proportion of patients with a localized EASI <2 at the end of study was higher with pimecrolimus cream 1% than with vehicle cream (73.5 vs. 39.4%, respectively). There was a significant decrease in the number of infiltrating CD45+ cells in pimecrolimus cream 1% compared with placebo cream (–88.2 vs. 43.2 cells/mm², respectively, p = 0.047) and a slight but nonsignificant reduction in the number of dermal dendritic cells, Langerhans cells, T cells and macrophages with pimecrolimus versus vehicle cream. Limitations: This was an exploratory study. Conclusion: Topical pimecrolimus was effective at maintaining betamethasone-17α-valerate-induced AD remission by inhibiting recurrences of the inflammatory infiltrate in the skin.

show abstract

Section: Discussionsupporting

confidence: 73%

“…The use of pimecrolimus cream 1% as an early intervention, at the first signs and/or symptoms of a relapse during the remission time, prevents the occurrence of major flares and prolongs the flare-free intervals [24,25,26,27,28,29]. With the present study, we began to explore the cellular events underlying this phenomenon.…”

Section: Introductionmentioning

confidence: 99%

Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial

Bangert

Strober²,

Cork³

et al. 2010

Dermatology

View full text Add to dashboard Cite

show abstract

“…The remaining 21 articles met all entry criteria and were included in the network meta-analysis. Among these studies, 3 articles were dual submissions and 1 study was divided into two comparisons; thus, only 19 [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25] treatment comparisons were included. The screening process is illustrated in figure 2.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis

Huang

2015

Dermatology

View full text Add to dashboard Cite

Objective: Using a network meta-analysis, we aimed to compare the efficacy and safety of tacrolimus and pimecrolimus as treatment options for children with atopic dermatitis (AD). Methods: Randomized controlled studies with a modified Jadad score >3 using tacrolimus or pimecrolimus in pediatric patients with AD were studied. Results: Out of 163 articles, 19 studies enrolling a total of 6,413 pediatric patients were selected. Pooled analysis revealed that tacrolimus 0.03% or 0.1% and pimecrolimus 1% were better at reducing eczema compared with vehicles. No significance was found between tacrolimus and pimecrolimus in improving the severity of eczema. More patients tended to withdraw in the vehicle groups compared to the tacrolimus and pimecrolimus groups. No significant difference existed between total adverse events and withdrawals in the tacrolimus and pimecrolimus groups. Conclusions: Pimecrolimus was similar to tacrolimus in both efficacy and safety for AD in children, but both were better than vehicles.

show abstract

“…Многочисленные исследования показали эффектив-ность и безопасность пимекролимуса при атопиче-ском дерматите [45][46][47]. Так, в исследовании S. L. Chen и соавт.…”

Section: топические ингибиторы кальциневринаunclassified

Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in Children

Мурашкин¹,

Материкин²,

Амбарчян³

et al. 2016

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis

Abstract: Early treatment of signs/symptoms of AD with pimecrolimus cream 1% provided an effective steroid-sparing option that reduced the incidence of major flares.

Cited by 44 publications

References 26 publications

Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial

Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial

Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis

Current Views on the Pathogenesis and Principles of External Treatment of Atopic Dermatitis in Children

Contact Info

Product

Resources

About